Risk model for overall survival for patients with relapsed/refractory chronic lymphocytic leukemia: Validated for patients on ibrutinib, idelalisib, venetoclax, or chemoimmuniotheraphy Meeting Abstract


Authors: Soumerai, J. D.; Ni, A.; Darif, M.; Londhe, A.; Xing, G.; Mun, Y.; Kay, N. E.; Shanafelt, T. D.; Chaffee, K. G.; Furman, R. R.; Hillmen, P.; Sharman, J.; Seymour, J. F.; Chanan-Khan, A. A.; Byrd, J. C.; Jones, J. A.; Ferrante, L. A.; Dreiling, L. K.; Mobasher, M.; Stark, T.; Reddy, V.; Howes, A. J.; James, D.; Bhargava, P.; Zelenetz, A. D.
Abstract Title: Risk model for overall survival for patients with relapsed/refractory chronic lymphocytic leukemia: Validated for patients on ibrutinib, idelalisib, venetoclax, or chemoimmuniotheraphy
Meeting Title: 60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 132
Issue: Suppl. 1
Meeting Dates: 2018 Dec 1-4
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2018-11-29
Language: English
ACCESSION: WOS:000454842804063
PROVIDER: wos
Notes: Meeting Abstract: 4394 -- Source: Wos